A Study of Retrovir in the Prevention of HIV Infection in Health Care Workers Accidentally Exposed to the Virus
Not Applicable
Completed
- Conditions
- HIV Infections
- Registration Number
- NCT00002287
- Lead Sponsor
- Glaxo Wellcome
- Brief Summary
To evaluate the safety and effectiveness of Retrovir (AZT) when used as prophylaxis for health care workers at risk for HIV infection from exposure to HIV-contaminated blood or blood components.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of AZT (Retrovir) contribute to its efficacy in post-exposure HIV prophylaxis for healthcare workers?
How does AZT compare to other NRTIs in preventing HIV infection after occupational exposure in clinical studies?
Are there specific biomarkers that predict AZT response in post-exposure prophylaxis for HIV in healthcare workers?
What are the known adverse events associated with AZT use in post-exposure HIV prophylaxis and how are they managed?
What combination therapies with AZT have been explored for HIV prevention in occupational exposure settings compared to monotherapy?
Trial Locations
- Locations (1)
Glaxo Wellcome Inc
🇺🇸Research Triangle Park, North Carolina, United States
Glaxo Wellcome Inc🇺🇸Research Triangle Park, North Carolina, United States